YD Bio CEO buys 3,100 shares at $3.93 avg

YD Bio’s CEO reported a modest open-market share purchase, increasing his direct holdings while also disclosing substantial indirect ownership via a trust.

Rhea-AI Filing Summary

YD Bio Ltd (YDES) director and CEO Dr. Ethan Shen reported an open-market purchase of 3,100 Ordinary Shares on September 9, 2026 at a weighted average price of $3.93 per share, executed in multiple transactions between $3.80 and $4.09. After this purchase, he holds 11,245,631 Ordinary Shares directly and additional shares indirectly through a trust structure of which he is the beneficial owner.

Insider Trade Summary

Net Buyer: 3,100 shares

Net Buy 2 txns

Insider Shen Ethan PhD

Role CEO

Bought 3,100 shs ($12K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares F1	3,100	$3.93	$12K
holding	Ordinary Shares F2	--	--	--

Holdings After Transaction: Ordinary Shares — 11,245,631 shares (Direct); Ordinary Shares — 43,120,858 shares (Indirect, See Footnotes)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.80 to $4.09, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.
2. F2. The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.

Key Figures

Shares purchased: 3,100 Ordinary Shares Weighted average purchase price: $3.93 per share Direct holdings after transaction: 11,245,631 Ordinary Shares +1 more

4 metrics

Shares purchased 3,100 Ordinary Shares Open-market purchase by CEO on September 9, 2026

Weighted average purchase price $3.93 per share Transactions executed between $3.80 and $4.09 on September 9, 2026

Direct holdings after transaction 11,245,631 Ordinary Shares Direct ownership by Dr. Shen following the September 9, 2026 purchase

Indirectly held shares 43,120,858 Ordinary Shares Held via YD Biopharma Holding Limited and The E820N Trust

Key Terms

weighted average price, beneficial owner, indirect, settlor

4 terms

weighted average price financial

"The price reported ... is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial owner regulatory

"Dr. Shen ... is the beneficial owner of such shares."

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

indirect financial

"The reported shares are held by YD Biopharma Holding Limited..."

settlor regulatory

"Dr. Shen is the settlor, protector and sole beneficiary of the Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did YDES report for Dr. Ethan Shen?

Dr. Ethan Shen reported an open-market purchase of 3,100 Ordinary Shares of YD Bio Ltd on September 9, 2026 at a weighted average price of $3.93 per share, executed in multiple transactions between $3.80 and $4.09.

How many YDES shares does Dr. Ethan Shen own directly after this Form 4?

After the reported purchase, Dr. Ethan Shen directly owns 11,245,631 Ordinary Shares of YD Bio Ltd. This figure is stated as his direct holdings immediately following the transaction reported on September 9, 2026.

What indirect YDES shareholding did Dr. Ethan Shen disclose?

The filing states that 43,120,858 Ordinary Shares are held indirectly, reported as held by YD Biopharma Holding Limited, which is wholly owned through intermediate entities by The E820N Trust, for which Dr. Shen is described as settlor, protector and sole beneficiary.

Was Dr. Ethan Shen’s YDES share purchase under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and there is no footnote indicating that the September 9, 2026 transactions were made pursuant to a Rule 10b5-1 trading plan.

What price range applied to Dr. Shen’s YDES share transactions on September 9, 2026?

The filing reports a weighted average price of $3.93 per share, with transactions executed at prices ranging from $3.80 to $4.09, inclusive. The reporting person undertakes to provide detailed trade breakdowns upon request.

What is Dr. Ethan Shen’s role at YD Bio Ltd (YDES)?

Dr. Ethan Shen is identified as both a director and the CEO of YD Bio Ltd in the Form 4, and the reported transactions relate to his holdings in the company’s Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:02 PM Accepted by SEC EDGAR 09/10/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shen Ethan PhD

(Last) (First) (Middle)

C/O YD BIO LIMITED

12F., NO. 3, XINGNAN ST., NANGANG DIST.

(Street)

TAIPEI CITY TAIWAN 115001

(City) (State) (Zip)

TAIWAN

(Country)

2. Issuer Name and Ticker or Trading Symbol
YD Bio Ltd [ YDES ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/09/2026		P		3,100	A	$3.93(1)	11,245,631	D
Ordinary Shares								43,120,858	I	See Footnotes(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.80 to $4.09, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.

2. The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.

	/s/ Ethan Shen	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)